<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2018 [PPXK5GW761L0VLLJM56S]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin:0'><B>UNITED STATES</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Washington, D. C. 20549</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>FORM 8-K</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CURRENT REPORT</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Pursuant to Section 13 Or 15(d) of the</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Securities Exchange Act of 1934</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Date of Report (Date of earliest event reported): September 21, 2018 </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Times New Roman;margin:0'><FONT style='font-size:12pt;border-bottom:1px solid #000000'><B>GB Sciences, Inc.</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Exact name of Registrant as specified in its charter)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>Delaware</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(State or other Jurisdiction of <BR>Incorporation or organization)</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>000-55462</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Commission File Number)</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>59-3733133</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(IRS Employer I.D. No.)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>3550 W. Teco Avenue</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Las Vegas, Nevada 89118  </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Phone: (844) 843-2569</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Address, including zip code, and telephone number, including area code, of</P>
<P align=center style='font:10pt Times New Roman;margin:0'>registrant&#8217;s principal executive offices)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>N/A</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Former name, former address and former fiscal year, if changed since last report)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P style='font:8pt Times New Roman;margin:0'> &nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'><FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD> &nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'><FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD>Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2)&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD> &nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'><FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD>Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b))&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD> &nbsp;</P>
<P style='font:8pt Times New Roman;margin:0'><KBD style='position:absolute;font:8pt Times New Roman;margin-left:0pt'><FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT> </KBD><KBD style='position:absolute;font:8pt Times New Roman;margin-left:36pt'> </KBD><KBD style=margin-left:72pt></KBD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c))&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'><FONT style=font-size:10pt><B>ITEM 5.02  Appointment of Chief Operations Officer and Senior Vice President of Cultivation.</B></FONT></P>
<P style='font:11pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:10pt;background-color:#FFFFFF>Effective September 21, 2018, Ksenia Griswold was appointed Chief Operations Officer of GB Sciences, Inc. (the &#8220;Company&#8221;), replacing Krin Ellery &#8220;Kevin&#8221; Kuethe who had been serving in that capacity. &nbsp;Effective the same day, Mr. Kuethe was appointed Senior Vice President of Cultivation. &nbsp;Ms. Griswold will also continue to service as the Chief Financial Officer of the Company. &nbsp;Compensation arrangements for Ms. Griswold and Mr. Kuethe with regard to their new appointments are being negotiated.</FONT></P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:10pt;background-color:#FFFFFF>Ms. Griswold has been serving as the controller of the Company since November 2015 and was appointed Chief Financial Officer on August 4, 2016. &nbsp;For the five years prior to November 2015, beginning in October 2010, she worked in the Las Vegas, Nevada office of Ernst &amp; Young, LLP. &nbsp;At the time of her departure from Ernst &amp; Young, she was audit manager. &nbsp;Ms. Griswold is 35 years of age.</FONT></P>
<HR style='border:0;height:0;width:0;margin:15pt 0 0 0'><P align=center style='font:10pt Calibri;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:10pt;background-color:#FFFFFF>Mr. Kuethe has been serving as the COO of the Company since November 2017. Mr. Kuethe is recognized as a leader nationwide for his extensive knowledge in the cannabis industry. In addition to overseeing development of production, retail, and cultivation operations on behalf of the Company, Mr. Kuethe has ensured the Company&#8217;s compliance with regulatory and operational requirements and manages two state-of-the-art medical cannabis cultivation facilities that total over 42,000 sq. ft. He has also been responsible for the development of operational design and vendor relationships. </FONT></P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:10pt;background-color:#FFFFFF>Mr. Kuethe has participated in all phases of development within the medical marijuana industry. Prior to joining the Company in June 2016, he setup, built out, and acquired approved licensing to manage and operate the fasted growing, state licensed cultivation and retail dispensary facilities in state of Arizona. He simultaneously designed and managed state-compliant facilities for the production of medical marijuana edibles and concentrates, and other dispensary services approved by the states of Arizona and California. &nbsp;In addition to providing operational roadmaps to ensure proven large scale commercial cannabis cultivation success, profitability, and compliance with regulatory standards, Mr. Kuethe has consulted and participated in various equity financing transactions which led him to own several successful businesses within the broad range of cannabis-industry support services and products. Mr. Kuethe&#8217;s facilities showcase the cutting-edge industry technology as well as provide key education to the county and state regarding finance, operations, and public interface. &nbsp;Mr. Kuethe is 33 years of age.</FONT></P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>SIGNATURE PAGE</B></FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=3 valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;  &nbsp;  &nbsp;&nbsp;GB Sciences, Inc.</B></FONT></P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>Dated: September 21, 2018</FONT></P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>By: </FONT></P>
</TD><TD valign=top style='border-bottom:1.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><FONT style=font-size:10pt>/s/ Ksenia Griswold</FONT></P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><FONT style=font-size:10pt>Ksenia Griswold</FONT></P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0;margin-left:18pt'><FONT style=font-size:10pt>Chief Financial Officer </FONT></P>
</TD><TD valign=middle><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:15pt 0 0 0'><P align=center style='font:10pt Calibri;margin:0'>2</P>
<P style='font:11pt Calibri;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "gblx_8k.htm", "description": "8-K", "secsgml_size_bytes": 13517}]
{"company-data": {"conformed-name": "GB SCIENCES INC", "cik": "0001165320", "assigned-sic": "1311", "irs-number": "593733133", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-55462", "film-number": "181082121"}, "business-address": {"street1": "6450 CAMERON STREET #110A", "city": "LAS VEGAS", "state": "NV", "zip": "89118", "phone": "(844) 843-2569"}, "mail-address": {"street1": "6450 CAMERON STREET #110A", "city": "LAS VEGAS", "state": "NV", "zip": "89118"}, "former-company": [{"former-conformed-name": "Growblox Sciences, Inc.", "date-changed": "20140603"}, {"former-conformed-name": "Signature Exploration & Production Corp.", "date-changed": "20080602"}, {"former-conformed-name": "Diabetic Treatment Centers of America, Inc.", "date-changed": "20040812"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2018
GB Sciences, Inc.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other Jurisdiction of
Incorporation or organization)
000-55462
(Commission File Number)
59-3733133
(IRS Employer I.D. No.)
3550 W. Teco Avenue
Las Vegas, Nevada 89118
Phone: (844) 843-2569
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2)
☐
Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c))
ITEM 5.02  Appointment of Chief Operations Officer and Senior Vice President of Cultivation.
Effective September 21, 2018, Ksenia Griswold was appointed Chief Operations Officer of GB Sciences, Inc. (the "Company"), replacing Krin Ellery "Kevin" Kuethe who had been serving in that capacity.  Effective the same day, Mr. Kuethe was appointed Senior Vice President of Cultivation.  Ms. Griswold will also continue to service as the Chief Financial Officer of the Company.  Compensation arrangements for Ms. Griswold and Mr. Kuethe with regard to their new appointments are being negotiated.
Ms. Griswold has been serving as the controller of the Company since November 2015 and was appointed Chief Financial Officer on August 4, 2016.  For the five years prior to November 2015, beginning in October 2010, she worked in the Las Vegas, Nevada office of Ernst & Young, LLP.  At the time of her departure from Ernst & Young, she was audit manager.  Ms. Griswold is 35 years of age.
1
Mr. Kuethe has been serving as the COO of the Company since November 2017. Mr. Kuethe is recognized as a leader nationwide for his extensive knowledge in the cannabis industry. In addition to overseeing development of production, retail, and cultivation operations on behalf of the Company, Mr. Kuethe has ensured the Company's compliance with regulatory and operational requirements and manages two state-of-the-art medical cannabis cultivation facilities that total over 42,000 sq. ft. He has also been responsible for the development of operational design and vendor relationships.
Mr. Kuethe has participated in all phases of development within the medical marijuana industry. Prior to joining the Company in June 2016, he setup, built out, and acquired approved licensing to manage and operate the fasted growing, state licensed cultivation and retail dispensary facilities in state of Arizona. He simultaneously designed and managed state-compliant facilities for the production of medical marijuana edibles and concentrates, and other dispensary services approved by the states of Arizona and California.  In addition to providing operational roadmaps to ensure proven large scale commercial cannabis cultivation success, profitability, and compliance with regulatory standards, Mr. Kuethe has consulted and participated in various equity financing transactions which led him to own several successful businesses within the broad range of cannabis-industry support services and products. Mr. Kuethe's facilities showcase the cutting-edge industry technology as well as provide key education to the county and state regarding finance, operations, and public interface.  Mr. Kuethe is 33 years of age.
SIGNATURE PAGE
Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GB Sciences, Inc.
Dated: September 21, 2018
By:
/s/ Ksenia Griswold
Ksenia Griswold
Chief Financial Officer
2